 | Up a level |
Bahlo, J., Goede, V, Kutsch, N., Fischer, K., Fink, A. -M, Stilgenbauer, S., Bergmann, M., Eichhorst, B. and Hallek, M. (2016). Evaluation of the international prognostic index for chronic lymphocytic leukemia (CLL-IPI) in elderly patients with comorbidities: Analysis of the CLL11 study population. Oncol. Res. Treat., 39. S. 5 - 7. BASEL: KARGER. ISSN 2296-5262
Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al-Sawaf, O., Langerbeins, P., Fuerstenau, M., Engelke, A., Fink, A. -M, Fischer, K., Kreuzer, K. -A, Ritgen, M., Boettcher, S., Wendtner, C. -M, Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2018). Comparison of 3 different phase II studies using sequential combinations of targeted agents to treat chronic lymphocytic leukemia. Oncol. Res. Treat., 41. S. 29 - 31. BASEL: KARGER. ISSN 2296-5262
Kutsch, N., Goede, V, Robrecht, S., Kelma, F., Bahlo, J., Fischer, K., Fink, A. -M, Schlag, R., Lange, E., Weide, R., Dreyling, M., Jaeger, U., Stilgenbauer, S., Doehner, H., Kneba, M., Ritgen, M., Wendtner, C. -M, Hallek, M. and Eichhorst, B. (2018). Treatment response and health-related quality of life during management of chronic lymphocytic leukemia (CLL) - a metaanalysis of 3 phase III studies of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 41. S. 30 - 31. BASEL: KARGER. ISSN 2296-5262
Pflug, N., Kluth, S., Vehreschild, J. J., Bahlo, J., Tacke, D., Biehl, L., Eichhorst, B., Fischer, K., Cramer, P., Fink, A. -M, von Bergwelt-Baildon, M., Hallek, M., Cornely, O. A. and Vehreschild, M. J. G. T. (2015). Impact of antibiotic treatment modulating the intestinal microbiota on the efficacy of antineoplastic treatment for chronic lymphatic leukaemia or relapsed lymphoma. Oncol. Res. Treat., 38. S. 175 - 176. BASEL: KARGER. ISSN 2296-5262
von Tresckow, J., Cramer, P., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M, Klaproth, H., Tausch, E., Fischer, K., Wendtner, C-M, Kreuzer, K. -A, Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2016). CLL2-BIG - a sequential treatment regimen of Bendamustine followed by GA101 and Ibrutinib followed by Ibrutinib and GA101 maintenance in patients with Chronic Lymphocytic Leukemia (CLL): Interim results of a phase II-trial by the German CLL Study Group. Oncol. Res. Treat., 39. S. 121 - 122. BASEL: KARGER. ISSN 2296-5262